These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 29203418)

  • 21. Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.
    Eslami L; Merat S; Malekzadeh R; Nasseri-Moghaddam S; Aramin H
    Cochrane Database Syst Rev; 2013 Dec; (12):CD008623. PubMed ID: 24374462
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adherence adjustment in the Coronary Drug Project: A call for better per-protocol effect estimates in randomized trials.
    Murray EJ; Hernán MA
    Clin Trials; 2016 Aug; 13(4):372-8. PubMed ID: 26951361
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment persistence and adherence and their consequences on patient outcomes of generic versus brand-name statins routinely used to treat high cholesterol levels in Spain: a retrospective cost-consequences analysis.
    Sicras-Mainar A; Sánchez-Álvarez L; Navarro-Artieda R; Darbà J
    Lipids Health Dis; 2018 Dec; 17(1):277. PubMed ID: 30522491
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Statins and secondary prevention of coronary heart disease.
    Ahmed M; Griffiths P
    Br J Community Nurs; 2004 Apr; 9(4):160-5. PubMed ID: 15150487
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Early statin initiation and outcomes in patients with acute coronary syndromes.
    Newby LK; Kristinsson A; Bhapkar MV; Aylward PE; Dimas AP; Klein WW; McGuire DK; Moliterno DJ; Verheugt FW; Weaver WD; Califf RM;
    JAMA; 2002 Jun; 287(23):3087-95. PubMed ID: 12069671
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A pharmacoeconomic evaluation of statins in the treatment of hypercholesterolaemia in the primary care setting in Spain.
    Tárraga-López PJ; Celada-Rodríguez A; Cerdán-Oliver M; Solera-Albero J; Ocaña-López JM; López-Cara MA; De Miguel-Clave J
    Pharmacoeconomics; 2005; 23(3):275-87. PubMed ID: 15836008
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Statins for secondary prevention in elderly patients: a hierarchical bayesian meta-analysis.
    Afilalo J; Duque G; Steele R; Jukema JW; de Craen AJ; Eisenberg MJ
    J Am Coll Cardiol; 2008 Jan; 51(1):37-45. PubMed ID: 18174034
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adherence to secondary prevention medications and four-year outcomes in outpatients with atherosclerosis.
    Kumbhani DJ; Steg PG; Cannon CP; Eagle KA; Smith SC; Hoffman E; Goto S; Ohman EM; Bhatt DL;
    Am J Med; 2013 Aug; 126(8):693-700.e1. PubMed ID: 23800583
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Replication of the Scandinavian Simvastatin Survival Study using a primary care medical record database prompted exploration of a new method to address unmeasured confounding.
    Weiner MG; Xie D; Tannen RL
    Pharmacoepidemiol Drug Saf; 2008 Jul; 17(7):661-70. PubMed ID: 18327857
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Statins and cancer risk.
    Karp I; Behlouli H; Lelorier J; Pilote L
    Am J Med; 2008 Apr; 121(4):302-9. PubMed ID: 18374689
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A model to assess the cost effectiveness of statins in achieving the UK National Service Framework target cholesterol levels.
    Wilson K; Marriott J; Fuller S; Lacey L; Gillen D
    Pharmacoeconomics; 2003; 21 Suppl 1():1-11. PubMed ID: 12648030
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An economic analysis of the Atorvastatin Comparative Cholesterol Efficacy and Safety Study (ACCESS).
    Smith DG; McBurney CR
    Pharmacoeconomics; 2003; 21 Suppl 1():13-23. PubMed ID: 12648031
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study.
    Athyros VG; Elisaf M; Papageorgiou AA; Symeonidis AN; Pehlivanidis AN; Bouloukos VI; Milionis HJ; Mikhailidis DP;
    Am J Kidney Dis; 2004 Apr; 43(4):589-99. PubMed ID: 15042535
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The cost-effectiveness of drug treatments for primary prevention of cardiovascular disease: a modelling study.
    Marshall T
    Eur J Cardiovasc Prev Rehabil; 2006 Aug; 13(4):523-8. PubMed ID: 16874140
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Analyzing intent-to-treat and per-protocol effects on safety outcomes using a medical information database: an application to the risk assessment of antibiotic-induced liver injury.
    Takeuchi Y; Shinozaki T; Kumamaru H; Hiramatsu T; Matsuyama Y
    Expert Opin Drug Saf; 2018 Nov; 17(11):1071-1079. PubMed ID: 30252549
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of efficacy and safety of atorvastatin (80 mg) to simvastatin (20 to 40 mg) in patients aged <65 versus >or=65 years with coronary heart disease (from the Incremental DEcrease through Aggressive Lipid Lowering [IDEAL] study).
    Tikkanen MJ; Holme I; Cater NB; Szarek M; Faergeman O; Kastelein JJ; Olsson AG; Larsen ML; Lindahl C; Pedersen TR;
    Am J Cardiol; 2009 Mar; 103(5):577-82. PubMed ID: 19231315
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Statins in elderly patients with acute coronary syndrome: an analysis of dose and class effects in typical practice.
    Choudhry NK; Levin R; Winkelmayer WC
    Heart; 2007 Aug; 93(8):945-51. PubMed ID: 17344334
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of intensive lipid lowering with atorvastatin on cardiovascular outcomes in coronary heart disease patients with mild-to-moderate baseline elevations in alanine aminotransferase levels.
    Tikkanen MJ; Fayyad R; Faergeman O; Olsson AG; Wun CC; Laskey R; Kastelein JJ; Holme I; Pedersen TR;
    Int J Cardiol; 2013 Oct; 168(4):3846-52. PubMed ID: 24001698
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Analysis and comparison of the cost-effectiveness of statins according to the baseline low-density lipoprotein cholesterol level in Korea.
    Jeong YJ; Kim H; Baik SJ; Kim TM; Yang SJ; Lee SH; Cho JH; Lee H; Yim HW; Choi IY; Yoon KH; Kim HS
    J Clin Pharm Ther; 2017 Jun; 42(3):292-300. PubMed ID: 28251662
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cardiovascular outcomes among patients newly initiating atorvastatin or simvastatin therapy: a large database analysis of managed care plans in the United States.
    Foody JM; Joyce AT; Rudolph AE; Liu LZ; Benner JS
    Clin Ther; 2008 Jan; 30(1):195-205. PubMed ID: 18343257
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.